Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer

Laura Evangelista, Zora Baretta, Lorenzo Vinante, Anna Rita Cervino, Michele Gregianin, Cristina Ghiotto, Giorgio Saladini, Guido Sotti

Research output: Contribution to journalArticlepeer-review


Purpose: The aim of the study was to assess the role of CA 15.3, CT and positron emission tomography (PET)/CT in patients with breast cancer and suspected disease relapse after primary treatment. Methods: We studied 111 consecutive patients (mean age 61±12 years) with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients underwent CT and 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT and CT. The final diagnosis of relapse was established by invasive and noninvasive follow-up and was compared with CA 15.3, CT and PET/CT results. Univariate and multivariate analyses were used to identify the independent predictors of disease relapse and receiver-operating characteristic (ROC) curve for the identification of optimal CA 15.3 cutoff. Results: Of all patients, 40 (36%) showed an increased CA 15.3 value, CT was positive in 73 (66%), whereas at PET/CT imaging 64 (58%) showed positive findings for disease relapse. Of 40 patients with increased marker levels, 22 patients had positive CT and 30 positive PET/CT (55 vs 75%, p

Original languageEnglish
Pages (from-to)293-301
Number of pages9
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number2
Publication statusPublished - Feb 2011


  • Breast cancer
  • Disease relapse
  • Follow-up
  • Positron emission tomography
  • Tumour markers

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer'. Together they form a unique fingerprint.

Cite this